Moreover, inhibition of USP10 significantly suppresses the proliferation of both imatinib-sensitive and imatinib-resistant CML cells, which likely depends on SKP2 status. The gene discussed is USP10; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.